Assessing drug effectiveness in colorectal cancer treatment using a new testing method
A Real-world Observational Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Colorectal Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method
This study is testing a new way to see how well certain drugs work for people with colorectal cancer by comparing treatment results with lab tests on their tissue samples.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 105 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | China Medical University, China Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06100016 on ClinicalTrials.gov |
What this trial studies
This observational clinical study focuses on patients diagnosed with colorectal cancer. It involves collecting tissue specimens before treatment to perform drug susceptibility testing using a novel method. The goal is to evaluate the consistency between clinical efficacy of anti-tumor treatments and the outcomes of the drug susceptibility tests. Patients will receive conventional treatments based on their doctors' medical judgment, and the study will analyze the effectiveness of these treatments in relation to the drug testing results.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 80 with a histopathologically confirmed diagnosis of colorectal cancer who require neoadjuvant, adjuvant, or palliative treatment.
Not a fit: Patients who are unable to provide fresh tumor specimens or have contraindications to chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for colorectal cancer patients.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in assessing drug susceptibility in cancer treatment, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female, aged ≥ 18 and ≤80; 2. Patients with colorectal cancer diagnosed by histopathology; 3. Patients who need neoadjuvant treatment; adjuvant therapy after radical surgery or palliative treatment; 4. Fresh tumor tissue specimens or malignant pleural effusion or ascites can be obtained; 5. Patients who sign the informed consent form, and are able to comply with the study period treatment process. Exclusion Criteria: 1. Inability to follow the research protocol; 2. Inability to obtain relevant fresh specimens by biopsy/surgery/puncture; 3. Concomitant contraindications to chemotherapy; 4. pregnant or lactating women; 5. Patients deemed inappropriate by investigators.
Where this trial is running
Shenyang, Liaoning
- Phase I Clinical Trials Center Of The First Hospital of China Medical University — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Principal investigator: Zhenning Wang, doctor — The First Affiliated Hospital of China Medical Univeristy
- Study coordinator: Shuhui Song, bachelor
- Email: 593900927@qq.com
- Phone: 02483281137
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.